Daniel S. Lynch

Daniel S. Lynch is Chairman of the Board of Beeline Medicines and a veteran biotechnology executive with decades of experience across the life sciences industry. Mr. Lynch is an Executive Venture Partner at GV, partnering with life sciences CEOs and executives as a trusted advisor. In addition to Beeline Medicines, he currently serves as a Board Member of Cardurion Pharmaceuticals and Delphia Therapeutics. Mr. Lynch has served as an executive chair or member of the Boards for a number of biopharmaceutical companies, including 2SeventyBio, Avila Therapeutics, bluebird bio, Blueprint Medicines, eGenesis Bio, Nimbus Discovery, Stromedix, SpringWorks Therapeutics, and Xilio Therapeutics. Earlier in his career, Mr. Lynch served as Chief Executive Officer and Chief Financial Officer of ImClone Systems, where he led the company through a significant turnaround and secured FDA approval of the novel cancer therapy Erbitux. Prior to that, he spent more than 15 years in financial leadership roles at Bristol Myers Squibb. Mr. Lynch holds an M.B.A. from University of Virginia Darden School of Business and a B.A. in mathematics from Wesleyan University.